Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: A Hoosier Oncology Group study

Journal of Clinical Oncology

Volumn 30, Issue 32, 2012, Pages 3998-4003

  Albany, Costantine ^a   Brames, Mary J ^a   Fausel, Christopher ^a   Johnson, Cynthia S ^a   Picus, Joel ^b   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; BLEOMYCIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; PLACEBO; SEROTONIN 3 ANTAGONIST;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; FATIGUE; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CROSS-OVER STUDIES; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS, GERM CELL AND EMBRYONAL; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 84869416865     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.5558     Document Type: Article

References (22)

1. Einhorn LH: Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99:4592-4595, 2002
2. Campos D, Pereira JR, Reinhardt RR, et al: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767, 2001
3. Gralla RJ, de Wit R, Herrstedt J, et al: Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: Analysis of combined data from two Phase III randomized clinical trials. Cancer 104:864-868, 2005
4. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin: The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003
5. American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006
6. Herrstedt J, Roila F: Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 19:ii110-ii112, 2008 (suppl 2)
7. Kris MG, Tonato M, Bria E, et al: Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 19:S25-S32, 2011 (suppl 1)
8. Einhorn LH, Grunberg SM, Rapoport B, et al: Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: Review and consensus statement. Support Care Cancer 19:S1-S4, 2011 (suppl 1)
9. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098, 2003
10. McCrea JB, Majumdar AK, Goldberg MR, et al: Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17-24, 2003
11. Hesketh PJ: Treatment of chemotherapy-induced emesis in the 1990s: Impact of the 5-HT3 receptor antagonists. Support Care Cancer 2:286-292, 1994
12. Herman TS, Einhorn LH, Jones SE, et al: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300:1295-1297, 1979
13. Cubeddu LX, Hoffmann IS, Fuenmayor NT, et al: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810-816, 1990
14. Einhorn LH, Nagy C, Werner K, et al: Ondansetron: A new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731-735, 1990
15. Hesketh PJ, Harvey WH, Harker WG, et al: A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596-600, 1994
16. Sledge GW Jr, Einhorn L, Nagy C, et al: Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524-2528, 1992
17. Cook AM, Dzik-Jurasz AS, Padhani AR, et al: The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Br J Cancer 85:1624-1626, 2001
18. Jobling AI, Augusteyn RC: What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 85:61-75, 2002
19. Vardy J, Chiew KS, Galica J, et al: Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011-1015, 2006
20. Einhorn LH, Brames MJ, Dreicer R, et al: Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293-1300, 2007
21. Lasseter KC, Gambale J, Jin B, et al: Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 47:834-840, 2007
22. Grunberg S, Chua D, Maru A, et al: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol - EASE. J Clin Oncol 29:1495-1501, 2011